| 94.04 -1.63 (-1.7%) | 10-21 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 133.82  |
1-year : | 148.8 |
| Resists | First : | 114.58 |
Second : | 127.4 |
| Pivot price | 100.34 |
|||
| Supports | First : | 93.83 |
Second : | 78.07 |
| MAs | MA(5) : | 96.09 |
MA(20) : | 104.6 |
| MA(100) : | 111.47 |
MA(250) : | 140.12 |
|
| MACD | MACD : | -6.5 |
Signal : | -5.9 |
| %K %D | K(14,3) : | 3.5 |
D(3) : | 4.5 |
| RSI | RSI(14): 27.4 |
|||
| 52-week | High : | 212.75 | Low : | 90.38 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.[ INSM ] has closed above bottom band by 17.3%. Bollinger Bands are 14% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 97.2 - 97.68 | 97.68 - 98.14 |
| Low: | 92.46 - 93.05 | 93.05 - 93.63 |
| Close: | 92.96 - 93.88 | 93.88 - 94.8 |
Insmed Incorporated operates as a biopharmaceutical enterprise focused on creating and introducing medical solutions for individuals facing severe and uncommon health conditions. The company's marketed treatment, ARIKAYCE, is administered to adult patients suffering from Mycobacterium avium complex (MAC) lung disease, serving as a component of a broader antibacterial drug regimen. In its development pipeline, Insmed is advancing Brensocatib, an oral and reversible inhibitor targeting dipeptidyl peptidase 1, which is being investigated for its potential in treating bronchiectasis and other disorders mediated by neutrophils. Additionally, the firm is developing Treprostinil Palmitil Inhalation Powder, an inhaled version of the treprostinil palmitil prodrug, designed to address pulmonary arterial hypertension and various other rare lung ailments. Founded in 1988, Insmed Incorporated maintains its primary corporate offices in Bridgewater, New Jersey.
Tue, 20 Oct 2026
Insmed Incorporated (INSM) Stock Price, News, Quote & History - Yahoo! Finance Canada
Tue, 20 Oct 2026
A no-cost grant gives Insmed (INSM) director Utpal Koppikar 6,139 stock units. - Stock Titan
Tue, 20 Oct 2026
A no-cost grant gives Insmed (INSM) director Paul Hudson 6,139 stock units. - Stock Titan
Tue, 20 Oct 2026
Insmed Appoints Two New Directors to Its Board - Insmed Incorporated Investor Relations
Tue, 20 Oct 2026
Insmed appoints Paul Hudson and Utpal Koppikar to its Board - TradingView
Mon, 19 Oct 2026
In Japan, patients can now get the only approved treatment for a lung disease that permanently widens airways. - Stock Titan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 218 (M) |
| Shares Float | 217 (M) |
| Held by Insiders | 0.5 (%) |
| Held by Institutions | 105 (%) |
| Shares Short | 13,800 (K) |
| Shares Short P.Month | 11,440 (K) |
| EPS | -4.1 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 3.47 |
| Profit Margin | -77 % |
| Operating Margin | -23.9 % |
| Return on Assets (ttm) | -22.2 % |
| Return on Equity (ttm) | -87.3 % |
| Qtrly Rev. Growth | 296.1 % |
| Gross Profit (p.s.) | 4.34 |
| Sales Per Share | 5.22 |
| EBITDA (p.s.) | -3.65 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -779 (M) |
| Levered Free Cash Flow | -572 (M) |
| PE Ratio | -22.94 |
| PEG Ratio | 1 |
| Price to Book value | 27.1 |
| Price to Sales | 18.01 |
| Price to Cash Flow | -26.37 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|